Since April 22, 2025, 503A enforcement discretion ended, and the FDA proposed in April 2026 to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List
Lexapro is FDA-approved to treat adults with major depressive disorder (depression) and general anxiety disorder (GAD)
Despite scarce data on GLP-1 distribution for Ozempic and Wegovy, studies report low patient adherence, as those still using the drugs drop to less than a third (32%) after the first year, then to 15% after year two
In terms of GLP1-RA use, there is an increased risk of gallbladder and biliary disease such as cholelithiasis and cholecystitis especially when these drugs are used for weight loss
Any changes made in dosage should be discussed with a doctor first, as each patients response may vary greatly among individuals